Overcoming proteasome inhibitor resistance in the immunotherapy era
Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …
Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial
P Sonneveld, A Chanan-Khan, K Weisel… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months),
daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged …
daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged …
Anti-tumor strategies by harnessing the phagocytosis of macrophages
SY Li, YL Guo, JW Tian, HJ Zhang, RF Li, P Gong… - Cancers, 2023 - mdpi.com
Simple Summary Macrophages are the “big eaters” of the immune system who are in charge
of engulfing undesirable substances. Macrophages are vital for the human body as they are …
of engulfing undesirable substances. Macrophages are vital for the human body as they are …
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib,
daratumumab, and dexamethasone (KdD) vs carfilzomib and dexamethasone (Kd) in adults …
daratumumab, and dexamethasone (KdD) vs carfilzomib and dexamethasone (Kd) in adults …
[HTML][HTML] Molecular and immunological mechanisms of clonal evolution in multiple myeloma
Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of
clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post …
clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post …
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy
Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell
transplantation (ASCT) has established itself as a core treatment for newly diagnosed …
transplantation (ASCT) has established itself as a core treatment for newly diagnosed …
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: the Mayo Clinic experience
POEMS (Polyneuropathy, Organomegaly, Endocrinopathies, Monoclonal protein, Skin
changes) syndrome is a rare paraneoplastic syndrome related to plasma cell disorders. The …
changes) syndrome is a rare paraneoplastic syndrome related to plasma cell disorders. The …
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study
JC Del Paggio, R Naipaul, S Gavura, RE Mercer… - The Lancet …, 2024 - thelancet.com
Background The financial impact of cancer medicines on health systems is not well known.
We describe temporal trends in expenditure on cancer medicines within the single-payer …
We describe temporal trends in expenditure on cancer medicines within the single-payer …
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple …
Background The primary analysis of the APOLLO trial, done after a median follow-up of 16· 9
months, showed that daratumumab plus pomalidomide and dexamethasone significantly …
months, showed that daratumumab plus pomalidomide and dexamethasone significantly …
New developments in myeloma treatment and response assessment
F Kraeber-Bodéré, B Jamet, D Bezzi… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Recent innovative strategies have dramatically redefined the therapeutic landscape for
treating multiple myeloma patients. In particular, the development and application of …
treating multiple myeloma patients. In particular, the development and application of …